Results 81 to 90 of about 43,122 (160)
HLA‐A*11:01 Identifies Patients at Risk for Persistent Viraemia and Advanced Fibrosis in HDV Infection
Alimentary Pharmacology &Therapeutics, Volume 64, Issue 10, Page 1432-1447, November 2026.The HLA‐A*11:01 allele is associated with persistent viraemia and advanced liver fibrosis in HDV infection. HLA‐A*11:01 carriers exhibit a reduced T‐cell repertoire, suggesting a narrower T‐cell response to the infection. ABSTRACT Background
Hepatitis delta virus (HDV) infection causes the most severe form of viral hepatitis, with highly heterogeneous ...Maria Francesca Cortese, Adriana Palom, Ariadna Rando Segura, Francesc Rudilla, Emma Enrich Rande, Arnau Puig Lopez, David Tabernero Caellas, Judit Vico Romero, Juan Carlos Ruiz‐Cobo, Mar Riveiro‐Barciela, Maria José Herrero, Maria Buti +11 morewiley +1 more sourceActinomicosis hepática [PDF]
, 1986 Se presenta un caso de actinomicosis hepática en su etapa de absceso. Se hace una revisión de la enfermedad en sus diversos aspectos, concluyendo en consideraciones confrontadas de la experiencia del caso con la bibliografía consultada.Facultad de ...Pagellá, Héctorcore Lack of Usefulness of Literature‐Based Helicobacter pylori Resistance Data for Predicting First‐Line Empirical Treatment Effectiveness in the European Registry on H. pylori Management (Hp‐EuReg)
Helicobacter, Volume 31, Issue 6, November/December 2026.ABSTRACT Background
Helicobacter pylori (H. pylori) infection causes gastritis, peptic ulcer disease, and gastric cancer. Without an effective vaccine, eradication therapy remains crucial. However, increasing antibiotic resistance compromises treatment effectiveness.Ismail Kirrout, Olga P. Nyssen, Ángeles Pérez‐Aísa, Bojan Tepes, Irina N. Voynovan, Samuel J. Martínez‐Domínguez, Alfredo J. Lucendo, Ludmila G. Vologzanina, Matteo Pavoni, Sayar R. Abdulkhakov, Maja Denkovski, Javier Tejedor‐Tejada, Tatiana Ilchishina, Luis Bujanda, Aiman S. Sarsenbaeva, Jose M. Huguet, Oleg Zaytsev, Boris D. Starostin, Monica Perona, Antonietta G. Gravina, Manuel Pabón‐Carrasco, Sergey A. Alekseenko, Óscar Núñez, Miguel Areia, Jesús Barrio, Antonio Moreno Loro, Dmitry N. Andreev, Blas José Gómez Rodríguez, María Soledad Marcos, Inmaculada Ortiz‐Polo, Galina N. Tarasova, Igor Bakulin, Mónica Sánchez Alonso, Irene Arteagoitia, Virginia Flores, Manuel Jiménez‐Moreno, Dmitry S. Bordin, Antonio Gasbarrini, Ricardo Marcos‐Pinto, Wojciech Marlicz, Perminder S. Phull, Marino Venerito, Doron Boltin, Lyudmila Boyanova, Pablo Parra, Leticia Moreira, Francis Mégraud, Colm O'Morain, Nuria Montes, Javier P. Gisbert, on behalf of the Hp‐EuReg investigators, Natalia N. Dekhnich, Pilar Mata‐Romero, Natalia Valerievna Bakulina, Alla G. Kononova, Giuseppe Losurdo, Judith Gomez‐Camarero, Alma Keco‐Huerga, Pablo M. Wolfe García, Jurij Bednarik, Eduardo Iyo, Antonia Perelló, Luis Fernández‐Salazar, Noelia Alcaide, Benito Velayos, Pedro Almela, Ramón Pajares Villarroya, Daniel Martin‐Holgado, Miguel Fernández‐Bermejo, Ian L. P. Beales, Alisan Kahraman, Ana Beatriz Pozo Blanco, Montserrat Planella, Mikel Ganuza, Victor A. Kamburov, Marina F. Osipenko, Debora Compare, Georges Kamtoh, Rosa Rosania, Eva Barreiro Alonso, Maria A. Livzan, Teresa Angueira, Consuelo Ramírez, Piotr Szredzki, Natalia Baryshnikova, Natalia Bakanova, Pedro Delgado Guillena, Sheyla Montori Pina, Eduardo Albéniz, Piotr Eder, Inna V. Savilova, Henrique Fernandes‐Mendes, Miguel Suárez Matías, María Badía Martínez, Liya Nikolaevna Belousova, Benito Hermida Pérez, Ana Garre, Natasa Brglez Jurecic, Olga Kolokolnikova, Paola Chaudarcas, Luis Hernández, Regina I. Khlynova, Antonio Cuadrado, Marta Pascual‐Mato, Ekaterina Y. Plotnikova, Mila Kovacheva‐Slavova, Ramiro Carreño Macián, Manon C. W. Spaander, Guillem Soy, Pilar Pazo Mejide, Sergio Gil Rojas, Carlos Maroto‐Martín, Francisco J. Rancel‐Medina, Diego Burgos‐Santamaría, Isabel Pérez‐Martínez, Giulia Fiorini, Teresa Valdés‐Lacasa, Riccardo Vasapolli, Rosa M. Sáiz‐Chumillas, Tamara Matysiak‐Budnik, Anna L. Pakhomova, Jorge Yebra Carmona, Diego Ledro Cano, Senador Moran Sanchez, Jan Bornschein, Pilar Bernal Checa, Antonio M. Caballero‐Mateos, Leticia Gimeno Pitarch, Ángela Martínez Herreros, Nerea Alonso‐Bilbao, Patricia Sanz‐Segura, Jose Xavier Segarra Ortega, Raquel García‐Sánchez, Alexander Link, Jesus M. Gonzalez‐Santiago, Laura Larrey Ruiz, Rodrigo Garcés‐Durán +136 morewiley +1 more sourceActinomicosis hepática [PDF]
, 2019 Se presenta un caso de actinomicosis hepática en su etapa de absceso. Se hace una revisión de la enfermedad en sus diversos aspectos, concluyendo en consideraciones confrontadas de la experiencia del caso con la bibliografía consultada.Facultad de ...Pagellá, Héctorcore Outcomes and Reclassification Patterns in Inflammatory Bowel Disease Unclassified: A Multicenter Study Matched With Ulcerative Colitis From Spanish ENEIDA Registry
Journal of Gastroenterology and Hepatology, Volume 41, Issue 11, Page 3413-3421, November 2026.ABSTRACT Background and Aim
Around 10% of patients with inflammatory bowel disease do not fulfill the diagnostic criteria for Crohn's disease (CD) or ulcerative colitis (UC). These cases are labelled as inflammatory bowel disease unclassified (IBDU).M. González‐Vivó, B. Castro Senosiain, I. Pérez‐Martínez, J. Barrio, P. Vega Villaamil, B. Caballol Oliva, V. Pedrera Roman, M. Piqueras Cano, F. Rodríguez Moranta, M. Iborra, M. J. Casanova, J. P. Gisbert, C. Tardillo Marin, L. Ramos, M. Urpi‐Ferreruela, R. H. Lorente Poyatos, M. Barreiro‐de Acosta, O. Belen Galipienso, L. Bujanda, Y. Zabana, F. Murciano, E. Domènech, L. Márquez‐Mosquera, on behalf of the
ENEIDA registry of GETECCU +23 morewiley +1 more sourceImpact of YAQ001 on the Gut Microbiome, Permeability and Markers of Systemic Inflammation in Patients With Cirrhosis
Liver International, Volume 46, Issue 11, November 2026.ABSTRACT Background & Aims
YAQ001 is a novel, non‐absorbable, gut‐restricted, multiporous, carbon bead adsorbent. Pre‐clinical studies and a clinical trial suggested its therapeutic potential and safety in patients with cirrhosis. This substudy aimed to explore the effects of YAQ001 on the gut microbiome and their exploratory association with ...Jinxia Liu, Fernando Garcia‐Guevara, Jane Macnaughtan, Yi Jin, Ainhoa Ferret‐Miñana, Frederick Clasen, Nicholas Yuen, Ramón Garcia Maset, Javier Ramón‐Azcón, Annarein J. C. Kerbert, Theo Portlock, Javier Martinez, Abeba Habtesion, Alexandra Phillips, Francesco De Chiara, Ganesh Ingavle, Tom Baldwin, Cesar Jimenez, Giacomo Zaccherini, Katherine Husi, Miguel Rodriguez‐Gandia, Paul Cordero‐Sanchez, Junpei Soeda, Jude A. Oben, Karen Church, Jia V. Li, Aarti Jalan, Adria Juanola, Elsa Sola, Simon Eaton, Carrie Morgan, Thomas Avery, Michal Kowalski, Daniel Green, Amir Gander, Lindsey Ann Edwards, I. Jane Cox, Helena Cortez‐Pinto, Reiner Wiest, Francois Durand, Paolo Caraceni, Roberto Elosua, Joan Vila, Marco Pavesi, Vicente Arroyo, Nathan Davies, Rajeshwar P. Mookerjee, Susan Sandeman, Gautam Mehta, Julian R. Marchesi, Agustin Albillos, Jennifer L. Rohn, Fausto Andreola, Saeed Shoaie, Rajiv Jalan +54 morewiley +1 more sourceSobrecrecimiento bacteriano intestinal: Mitos y realidades
Atención PrimariaResumen: El obrecrecimiento bacteriano intestinal (SIBO, por sus siglas en inglés) es un trastorno clínico resultante de la colonización del intestino delgado por un número excesivo de microorganismos o por microorganismos no habituales.Antonio Guardiola-Arévalo, Juanjo Mascort Roca, Mar Noguerol Álvarez, Ricard Carrillo Muñoz, Juan Manuel Mendive Arbeloa, Javier Amador Romero +5 moredoaj +1 more source